Esperion Therapeutics (NASDAQ:ESPR) Rating Increased to Neutral at JPMorgan Chase & Co.

JPMorgan Chase & Co. upgraded shares of Esperion Therapeutics (NASDAQ:ESPRGet Rating) from an underweight rating to a neutral rating in a report published on Wednesday morning, The Fly reports. The brokerage currently has $6.00 price target on the biopharmaceutical company’s stock.

A number of other equities analysts have also weighed in on ESPR. Northland Securities decreased their price target on shares of Esperion Therapeutics from $10.00 to $5.00 in a report on Wednesday, January 12th. StockNews.com assumed coverage on Esperion Therapeutics in a report on Thursday, March 31st. They issued a sell rating on the stock. HC Wainwright assumed coverage on Esperion Therapeutics in a research note on Thursday, March 10th. They set a buy rating and a $22.00 price target for the company. Finally, Credit Suisse Group reduced their price objective on Esperion Therapeutics from $8.00 to $6.00 and set a neutral rating on the stock in a research note on Friday, January 14th. Three investment analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of Hold and an average price target of $25.55.

Shares of NASDAQ:ESPR opened at $6.38 on Wednesday. The business has a fifty day simple moving average of $5.08 and a 200-day simple moving average of $5.65. Esperion Therapeutics has a 52 week low of $3.28 and a 52 week high of $26.77.

Esperion Therapeutics (NASDAQ:ESPRGet Rating) last issued its quarterly earnings results on Tuesday, May 3rd. The biopharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.11. The business had revenue of $18.84 million during the quarter, compared to analyst estimates of $15.41 million. During the same period in the previous year, the business posted ($3.50) earnings per share. The firm’s quarterly revenue was up 136.1% on a year-over-year basis. On average, research analysts anticipate that Esperion Therapeutics will post -3.62 earnings per share for the current fiscal year.

A number of large investors have recently modified their holdings of the business. Wasatch Advisors Inc. raised its stake in shares of Esperion Therapeutics by 95.0% during the fourth quarter. Wasatch Advisors Inc. now owns 6,386,263 shares of the biopharmaceutical company’s stock valued at $31,931,000 after purchasing an additional 3,111,903 shares during the period. Deep Track Capital LP purchased a new stake in Esperion Therapeutics during the 4th quarter worth $28,208,000. Deerfield Management Company L.P. Series C purchased a new stake in Esperion Therapeutics during the 4th quarter worth $25,000,000. Meditor Group Ltd lifted its holdings in Esperion Therapeutics by 58.5% in the 4th quarter. Meditor Group Ltd now owns 4,468,835 shares of the biopharmaceutical company’s stock worth $22,344,000 after buying an additional 1,650,000 shares in the last quarter. Finally, Altium Capital Management LP purchased a new position in Esperion Therapeutics in the 4th quarter valued at about $12,579,000.

Esperion Therapeutics Company Profile (Get Rating)

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.

Read More

The Fly logo

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.